New vaccine aims to stop Virus-Linked cancers in organ transplant patients
NCT ID NCT06741072
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transplant candidates to see if the vaccine is safe and triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 5 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OSU-2131 (a peptide vaccine) with QS-21 adjuvant
What this could lead to
If it works, this could lead to a vaccine that prevents EBV-related cancers in transplant patients.
What could go wrong
This is a very early phase 1 trial focused on safety, so it may not prove effective. The study is currently suspended, and results are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.